Research libraryMOLEKUL / SOURCE RECORD

The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.

Radchenko AI, Kuzubova EV, Apostol AA, Mitkevich VA, Andreeva LA, Limborska SA, Stepenko YV, Shmigerova VS, Solin AV, Korokin MV, Pokrovskii MV, Myasoedov NF, Makarov AA · 2025 · Acta naturae; 2025 Oct-Dec

Animal / experimentalFull text availableSource linked
This is Molekul’s research summary, not the original publication. Educational information only, not medical advice. Seek qualified healthcare help for medical conditions.

Study findings

Semax and a separately tested derivative improved behavioral measures and reduced amyloid inclusions in the cortex and hippocampus.

Population and setting
Transgenic APPswe/PS1dE9/Blg mice
Evidence type
Animal / experimental
Preparation
See the original report; formulation details require verification.
Source language
eng
Title source
Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

Study limitations

  • An animal Alzheimer’s model does not establish clinical efficacy or safety in people.
  • The derivative and Semax are distinct preparations; results must not be treated as interchangeable.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Source access and review scope

Indexed record and abstract checked. Full methods and risk of bias have not been independently assessed. Open full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC12755871/

Recorded source-check date: 2026-10-06. This date does not imply a completed systematic review.

Open original source or index record ↗

DOI: 10.32607/actanaturae.27808

Citation and original source

Original source: Radchenko AI, Kuzubova EV, Apostol AA, Mitkevich VA, Andreeva LA, Limborska SA, Stepenko YV, Shmigerova VS, Solin AV, Korokin MV, Pokrovskii MV, Myasoedov NF, Makarov AA. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta naturae; 2025 Oct-Dec 2025.

Molekul research summary: https://molekul.io/research/recent-41479572. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Bibliography entry

Related compound profiles

Editorial policy and evidence standards